Progressive pulmonary fibrosis and Idiopathic pulmonary fibrosis research hub

IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis

This study looks at the long-term safety of a medicine called admilparant for people with pulmonary fibrosis. Researchers want to see how well the body handles the treatment over time, tracking any side effects and checking heart health and blood tests to make sure it is safe to use.